Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

NCT03892044 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Richter Syndrome
Small Lymphocytic Lymphoma
Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Duvelisib
BIOLOGICAL: Nivolumab

Sponsor

David Bond, MD